EyePoint provides company update, anticipated milestones

EyePoint (EYPT) Pharmaceuticals provided a company update and anticipated 2025 milestones for its lead product candidate, DURAVYU, f/k/a EYP-1901. DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E for sustained intraocular delivery. Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule. Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025. “2024 was an exceptional year for EyePoint, positioning us for continued success and execution in 2025,” said Jay Duker, M.D., President and Chief Executive Officer. “Most importantly, as we step into 2025, both of our global Phase 3 clinical trials for DURAVYU in wet AMD are now fully underway with enrollment in both trials exceeding our expectations. The LUGANO trial has already enrolled approximately one-third of planned patients, and the LUCIA trial is tracking ahead of schedule after an accelerated initiation in December.”